Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Market Cap	389.88M +119.2%
Revenue (ttm)	55.93M +759.1%
Net Income	23.65M
EPS	1.11
Shares Out	20.01M
PE Ratio	17.52
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	149,017
Average Volume	236,897
Open	19.60
Previous Close	19.70
Day's Range	19.48 - 20.35
52-Week Range	5.20 - 31.85
Beta	0.76
RSI	35.93
Earnings Date	Mar 24, 2026

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: NWRN

Financial Performance

Financial numbers in EUR